🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

58 results for “Daiichi Sankyo” Clear

  1. CS-3150

    Daiichi Sankyo

    Diabetic Nephropathy

    phase 2 small molecule completed

    1 trial

  2. DS-1062a

    Daiichi Sankyo

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  3. DS-3939a

    Daiichi Sankyo

    Metastatic Solid Tumor, Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  4. DS-5141b

    Daiichi Sankyo

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  5. DS-8201a

    Daiichi Sankyo

    Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer

    phase 2 small molecule active

    1 trial

  6. Datopotamab deruxtecan

    Daiichi Sankyo

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  7. EPCORITAMAB, RITUXIMAB

    Daiichi Sankyo

    Hematological Malignancies

    phase 2 small molecule active

    1 trial

  8. HER3-DXd

    Daiichi Sankyo

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  9. Ifinatamab deruxtecan

    Daiichi Sankyo

    Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma)

    phase 2 small molecule active

    1 trial

  10. Ifinatamab deruxtecan

    Daiichi Sankyo

    Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  11. Patritumab deruxtecan

    Daiichi Sankyo

    Metastatic or Locally Advanced EGFR mutated Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  12. Patritumab deruxtecan

    Daiichi Sankyo

    Locally Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  13. Quizartinib

    Daiichi Sankyo

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  14. Raludotatug Deruxtecan

    Daiichi Sankyo

    Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC)

    phase 2 small molecule active

    1 trial

  15. Valemetostat Tosylate, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Valemetostat Tosylate

    Daiichi Sankyo

    Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    Relapsed/Refractory Peripheral T-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  17. olmesartan medoxomil

    Daiichi Sankyo

    Chronic Glomerulonephritis

    phase 2 small molecule completed

    1 trial

  18. DS-1205c

    Daiichi Sankyo

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 small molecule terminated

    1 trial

  19. Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin.

    Daiichi Sankyo

    No medical condition.

    phase 1 other active

    1 trial

  20. Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin.

    Daiichi Sankyo

    No medical condition.

    phase 1 other active

    1 trial

  21. Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin.

    Daiichi Sankyo

    No medical condition

    phase 1 other active

    1 trial

  22. Evaluating Bioequivalence of a Fixed Dose Combination versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin.

    Daiichi Sankyo

    No medical condition.

    phase 1 other active

    1 trial

  23. First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors

    Daiichi Sankyo

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  24. First-in-Human trial of DS9051b in participants with advanced solid tumors

    Daiichi Sankyo

    Advanced or Metastatic Adrenocortical Carcinoma (ACC), Metastatic Castration-resistant Prostate Cancer (CRPC)

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources